Immunotherapy's Promise Extends to Bladder and Renal Cell Cancer
News stories coming out of the 7th European Multidisciplinary
Meeting on Urological Cancers (EMUC) were
focused on the emerging role of immunotherapy and
radiotherapy in bladder, renal, and prostate cancer.
Men With High-Risk Prostate Cancer Undergoing More Prostatectomies
Recent trends suggest a shift away from radiation therapy and more toward radical prostatectomy for patients with high-risk prostate cancer.
Personalized Peptide Vaccination Increased Survival in Advanced Bladder Cancer
The prognosis for patients with bladder cancer who have progressed after platinum-based chemotherapy is poor, but the results of a phase II study involving an immunotherapy hold promise.
Swedish Biomarker Test STHLM3 Identifies Aggressive Form of Prostate Cancer
A test called the Stockholm 3 (STHLM3) has been shown to detect aggressive prostate cancer cancer earlier, reduce the number of false positives, and decrease the number of unnecessary biopsies.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512